1. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. Issue 3 (9th November 2020) Authors: Baer, Alan N; Gottenberg, Jacques-Eric; St Clair, E William; Sumida, Takayuki; Takeuchi, Tsutomu; Seror, Raphaèle; Foulks, Gary; Nys, Marleen; Mukherjee, Sumanta; Wong, Robert; Ray, Neelanjana; Bootsma, Hendrika Journal: Annals of the rheumatic diseases Issue: Volume 80:Issue 3(2021) Page Start: 339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0039 EFFICACY AND SAFETY OF ABATACEPT IN ACTIVE PRIMARY SJÖGREN'S SYNDROME: RESULTS OF A RANDOMISED PLACEBO-CONTROLLED PHASE III TRIAL. (June 2019) Authors: Baer, Alan; Gottenberg, Jacques-Eric; E., William St. Clair; Sumida, Takayuki; Takeuchi, Tsutomu; Seror, Raphaèle; Foulks, Gary; Nys, Marleen; Johnsen, Alyssa; Wong, Robert; Ray, Neelanjana; Bootsma, Hendrika Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Safety of KPI-121 Ophthalmic Suspension 0.25% in Patients With Dry Eye Disease: A Pooled Analysis of 4 Multicenter, Randomized, Vehicle-Controlled Studies. Issue 5 (May 2021) Authors: Korenfeld, Michael; Nichols, Kelly K.; Goldberg, Damien; Evans, David; Sall, Ken; Foulks, Gary; Coultas, Susan; Brazzell, Kim Journal: Cornea Issue: Volume 40:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗